A step forward for HIV vaccines.
作者信息
Barouch Dan H
机构信息
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
出版信息
Lancet HIV. 2018 Jul;5(7):e338-e339. doi: 10.1016/S2352-3018(18)30095-X. Epub 2018 Jun 10.
Abstract
摘要
相似文献
1
A step forward for HIV vaccines.艾滋病疫苗向前迈进了一步。
Lancet HIV. 2018 Jul;5(7):e338-e339. doi: 10.1016/S2352-3018(18)30095-X. Epub 2018 Jun 10.
2
Uhambo - Twists and Turns on the Journey to an Efficacious HIV-1 Vaccine.
N Engl J Med. 2021 Mar 25;384(12):1157-1159. doi: 10.1056/NEJMe2102358.
3
Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.1型人类免疫缺陷病毒候选疫苗Env 2-3与新型佐剂MTP-PE/MF59联合使用的安全性和免疫原性。美国国立过敏和传染病研究所艾滋病疫苗评估小组。
AIDS Res Hum Retroviruses. 1996 May 20;12(8):683-93. doi: 10.1089/aid.1996.12.683.
4
Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine.接受1型人类免疫缺陷病毒（HIV-1）重组gp120疫苗的新生儿体内的HIV-1 gp120特异性抗体。
J Infect Dis. 2001 Nov 15;184(10):1331-5. doi: 10.1086/323994. Epub 2001 Oct 10.
5
DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies.恒河猴的DNA-MVA-蛋白质疫苗接种可在黏膜相关淋巴结中诱导HIV特异性免疫和功能性抗体。
Vaccine. 2017 Feb 7;35(6):929-937. doi: 10.1016/j.vaccine.2016.12.060. Epub 2017 Jan 6.
6
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.C 亚型 ALVAC-HIV 和双价 C 亚型 gp120/MF59 HIV-1 疫苗在南非低危、未感染 HIV 的成年人中的 1/2 期临床试验
Lancet HIV. 2018 Jul;5(7):e366-e378. doi: 10.1016/S2352-3018(18)30071-7. Epub 2018 Jun 18.
7
Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1.MF59中的微粒，一种用于抗HIV-1重组蛋白疫苗的有效佐剂组合。
Vaccine. 2000 Mar 6;18(17):1793-801. doi: 10.1016/s0264-410x(99)00522-8.
8
Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge.候选HIV-1 gp140DeltaV2、Gag和Tat疫苗可抵御实验性HIV-1/MuLV攻击。
Vaccine. 2007 Sep 28;25(39-40):6882-90. doi: 10.1016/j.vaccine.2007.07.012. Epub 2007 Jul 27.
9
Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.恒河猴中核酸、MF59和免疫刺激复合物（ISCOM）配方的1型人类免疫缺陷病毒疫苗所产生的免疫比较：病毒清除的证据
J Virol. 1999 Apr;73(4):3292-300. doi: 10.1128/JVI.73.4.3292-3300.1999.
10
Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.研发双价蛋白增强剂以用于未来临床试验：含有效佐剂的 HIV-1 亚型 CR01_AE 和 B gp120 抗原。
PLoS One. 2018 Apr 26;13(4):e0194266. doi: 10.1371/journal.pone.0194266. eCollection 2018.
引用本文的文献
1
Adherence to a Vaccination Schedule in a Simulated HIV Vaccine Efficacy Trial Among Adults in Fishing Communities Around Lake Victoria, Uganda.乌干达维多利亚湖周边渔业社区成年人模拟HIV疫苗效力试验中的疫苗接种计划依从性
Vaccines (Basel). 2025 May 13;13(5):515. doi: 10.3390/vaccines13050515.
2
Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy.细胞膜锚定的抗 HIV 单链抗体和针对 gp41 融合蛋白的双功能抑制剂：HIV 基因治疗的新策略。
Emerg Microbes Infect. 2022 Dec;11(1):30-49. doi: 10.1080/22221751.2021.2011616.
3
Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy.用单域抗体生成抗 HIV 细胞：对 HIV-1 基因治疗的影响。
Cell Mol Immunol. 2021 Mar;18(3):660-674. doi: 10.1038/s41423-020-00627-y. Epub 2021 Jan 18.
4
Willingness of female sex workers in Kampala, Uganda to participate in future HIV vaccine trials: a case control study.乌干达坎帕拉的女性性工作者参与未来 HIV 疫苗试验的意愿：一项病例对照研究。
BMC Public Health. 2020 Nov 25;20(1):1789. doi: 10.1186/s12889-020-09932-7.
5
Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions.艾滋病疫苗研发的主要科学障碍：历史回顾与未来方向。
Front Immunol. 2020 Oct 28;11:590780. doi: 10.3389/fimmu.2020.590780. eCollection 2020.
6
Bringing the path toward an HIV-1 vaccine into focus.使HIV-1疫苗的研发之路更加清晰。
PLoS Pathog. 2020 Sep 10;16(9):e1008663. doi: 10.1371/journal.ppat.1008663. eCollection 2020 Sep.
7
Factors associated with vaccination completion and retention among HIV negative female sex workers enrolled in a simulated vaccine efficacy trial in Kampala, Uganda.与乌干达坎帕拉一项模拟疫苗功效试验中入组的 HIV 阴性女性性工作者的疫苗接种完成和保留相关的因素。
BMC Infect Dis. 2019 Aug 16;19(1):725. doi: 10.1186/s12879-019-4328-1.
本文引用的文献
1
An HIV Vaccine Is Essential for Ending the HIV/AIDS Pandemic.一种HIV疫苗对于终结HIV/AIDS大流行至关重要。
JAMA. 2017 Oct 24;318(16):1535-1536. doi: 10.1001/jama.2017.13505.
2
New concepts in HIV-1 vaccine development.HIV-1疫苗研发的新概念。
Curr Opin Immunol. 2016 Aug;41:39-46. doi: 10.1016/j.coi.2016.05.011. Epub 2016 Jun 3.
3
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.增加 HIV-1 疫苗对具有 Env V2 遗传特征的病毒的功效。
Nature. 2012 Oct 18;490(7420):417-20. doi: 10.1038/nature11519. Epub 2012 Sep 10.
4
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.HIV-1 疫苗功效试验的免疫相关性分析。
N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.
5
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.在泰国使用ALVAC和AIDSVAX疫苗预防HIV-1感染。
N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20.
Zotero 插件